Study of TB and HIV co-infection outcomes
Part of Immune system & allergy, Infections clinical trials.
This study looks at the health of people who have both tuberculosis (TB) and HIV. It helps doctors understand how the two infections affect each other and what treatments work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a lab test showing you have both TB and HIV.
- You must be willing to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking the long-term health of people living with HIV who receive care at a specific hospital clinic. It aims to better understand HIV over time.
This study follows people who have tested positive for HIV. It aims to better understand HIV over time, but you can only participate if you agree to join the study.
This study compares two different HIV medication regimens in people who have both HIV and active tuberculosis (TB) and are starting HIV treatment for the first time. The goal is to see which combination works better and is safer when taken together with TB medications.
This study follows HIV patients taking antiretroviral therapy (HIV medications) to understand how well treatment works, especially in people who also have serious infections like tuberculosis, fungal infections, or other opportunistic infections. Researchers will track your health over time to improve treatment outcomes.
This study looks for tuberculosis (TB) in people with HIV who have no symptoms. It aims to understand how common hidden TB is, which could lead to better detection and prevention.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
Hear when a new Mycobacterium Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.